ClinicalTrials.gg
CompletedNCT02321397Updated Nov 4, 2016

To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain

A Phase 2/3 interventional study of Oxycodone and Naloxone in Malignant Pain and Non-malignant Pain, sponsored by Mundipharma Research GmbH & Co KG. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-04.

Sponsored by Mundipharma Research GmbH & Co KG (part of Mundipharma) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 62 studies in Bronchiolitis Obliterans Syndrome with a site in Germany — 7 open to participants now, 12 under way, 4 of them phase 3. Bronchiolitis Obliterans Syndrome · Germany.

Enrollment
31st of 56
155 · median 173
Started
2014
with 3 others
Phase 2/3
3 of 62
none open now
Registered
29th of 62
by date

Among the 62 studies in Bronchiolitis Obliterans Syndrome with a site in Germany, this one is the 31st largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2014, is one of 3 in phase 2/3, and was the 29th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

7 of the 62 studies in Bronchiolitis Obliterans Syndrome with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Bronchiolitis Obliterans Syndrome with a site in Germany, or all of them as a file.
02

Study summary

This study is aimed to demonstrate equivalence between combinations of lower strength OXN PR tablets (OXN PR LST) and single higher strength OXN PR tablets (OXN PR HST) taken at the same overall daily dose.

Read the detailed description

Study OXN3508 is a multicenter double-blind, double-dummy, randomised, cross-over, 2-period, phase III study in male and female subjects with severe non-malignant or malignant pain that requires around-the-clock opioid therapy at a daily dose of 120/60 mg or 160/80 mg oxycodone/naloxone prolonged release (OXN PR).

03

Conditions studied

  • Malignant Pain
  • Non-malignant Pain

Keywords

  • oxycodone naloxone combination
  • severe chronic and non-malignant pain
  • Malignant and non-malignant pain that requires around-the clock opioid therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are receiving WHO step III opioid analgesic medication for the treatment of non-malignant or malignant pain.
  • Documented history of non-malignant or malignant pain that requires around-the-clock opioid therapy

Exclusion criteria

Exclusion Criteria

  • Females who are pregnant or lactating.
  • Subjects with evidence or significant structural abnormalities of the gastrointestinal tract.
  • Subjects with evidence of impaired liver/kidney function upon entry into the study.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    OXN PR HST

    Prolonged release oxycodone/naloxone higher strength tablets

    Drug: Oxycodone

  • Active comparator
    OXN PR LST

    Prolonged release oxycodone/naloxone lower strength tablets

    Drug: Naloxone

Interventions

06

What researchers measure

Primary outcomes

  1. (mean of subjects average pain over the last 24 hours as assessed by the pain intensity scale.)

    Pain scores based on the mean of subjects average pain over the last 24 hours as assessed by the pain intensity scale. To demonstrate equivalence between multiple lower strength OXN PR tablets and a single higher strength OXN PR tablet taken at the same overall total daily dose

    Time frame: 24 hours at one day in week 2, 3 5 and 6 from date of randomisation.

  2. Equivalent bowel function as assessed by the Bowel Function Index (BFI).

    Time frame: Week 2, 3 5 and 6 from date of randomisation.

Secondary outcomes

  1. Pain scores of subjects average pain over the last 24 hours and rescue medication use.

    Time frame: Week 1,2,3,4,5 and 6 from date of randomisation

  2. To assess bowel function (assess BFI and laxative use)

    To assess BFI and laxative use

    Time frame: Week 1,2,3,4,5 and 6 from date of randomisation

  3. To assess quality of life based on the EuroQol EQ-5D.

    EuroQol EQ-5D is a standardized instrument for use as a measure of health outcome.

    Time frame: Visit 3 and visit 6 from date of randomisation

  4. Number of participants with adverse events, high/low laboratory values and clinically significant ECG findings.

    Time frame: Up to 35 weeks

  5. Pain right now scores at intake of oxycodone/naloxone tablets.

    Time frame: Week 2,3,5 and 6 from date of randomisation

07

Study locations

1 site
  • Mainz, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Mar 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2014
First posted
Dec 22, 2014
Start
Nov 2014
Primary completionActual
Mar 2016
CompletionActual
Sep 2016
Last update
Nov 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02321397
Responsible party
Sponsor
First posted
Dec 22, 2014
Start date
Nov 2014
Primary completion
Mar 2016
Completion
Sep 2016
Last update
Nov 4, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion